{"prompt": "['2017N331008_06', 'CONFIDENTIAL', '208090', '5.', 'STUDY POPULATION', 'Specific information regarding warnings, precautions, contraindications, adverse events,', 'and other pertinent information on the investigational product or other study interventions', 'that may impact participant eligibility is provided in the Product Insert(s) for DTG, 3TC', 'or CAR.', 'Deviations from inclusion and exclusion criteria are not allowed because they can', 'potentially jeopardize the scientific integrity of the study, regulatory acceptability or', 'participant safety. Therefore, adherence to the criteria as specified in the protocol is', 'essential. Prospective approval of protocol deviations to recruitment and enrolment', 'criteria, also known as protocol waivers or exemptions, is not permitted.', 'The following are study specific eligibility criteria unless stated otherwise. In addition to', 'these criteria, Investigators must exercise clinical discretion regarding selection of', 'appropriate study participants, taking into consideration any local treatment practices or', 'guidelines and good clinical practice (GCP).', 'Laboratory results provided from central laboratory services will be used to assess', 'eligibility. In exceptional circumstances only, if a central lab result cannot be generated,', 'local labs can be reviewed and approved by the Medical Monitor, for consideration of', 'participant eligibility, except for plasma HIV-1 RNA.', '5.1.', 'Inclusion Criteria', 'Eligible participants must:', 'be able to understand and comply with protocol requirements, instructions, and', 'restrictions;', 'be likely to complete the study as planned;', 'be considered appropriate candidates for participation in an investigative clinical', 'trial with oral medication (e.g. no active problematic substance abuse, acute major', 'organ disease, or potential long-term work assignments out of the country).', 'Participants are eligible to be included in the study only if all of the following', 'criteria apply:', 'Age', '1. Aged 18 years or older (or older, if required by local regulatory agencies), at the', 'time of signing the informed consent.', 'Type of Participant and Disease Characteristics', '2. Adults living with HIV', '38']['2017N331008_06', 'CONFIDENTIAL', '208090', '3. Documented evidence of at least two plasma HIV-1 RNA measurements', '<50 c/mL in the 12 months prior to Screening: one within the 6 to 12 month', 'window, and one within 6 months prior to Screening.', '4. Plasma HIV-1 RNA <50 c/mL at Screening.', '5. Must be on uninterrupted current regimen (either the initial or second cART', 'regimen) for at least 3 months prior to Screening.', 'Any prior switch, defined as a change of a single drug or multiple drugs', 'simultaneously, must have occurred due to tolerability and/or safety concerns or', 'access to medications, or convenience/simplification and must NOT have been', 'done for suspected or established treatment failure. The following switches, if', 'they are the only switches, would not be considered a change in regimen:', 'a.', 'A switch from a PI boosted with RTV to the same PI boosted with cobicistat', 'is allowed (and vice versa).', 'b. A switch from lamivudine (3TC) to emtricitabine (FTC) (and vice versa)', 'c.', 'A switch from tenofovir disoproxil fumarate (TDF) to tenofovir', 'alafenamide (TAF) (and vice versa)\"', 'Acceptable stable cART regimens prior to Screening include 2 NRTIs plus:', 'INI (either the initial or second cART regimen)', 'NNRTI (either the initial or second cART regimen)', 'Boosted PI (or atazanavir [ATV] unboosted) (either the initial or second PI-based', 'cART regimen)', 'NOTE: Combination triple ART <10 days with any antiretroviral agent following a', 'diagnosis of HIV-1 infection is not considered a prior cART regimen.', 'Sex', '6. Male and Female', 'a. Female participants:', 'A female participant is eligible to participate if she is not pregnant [as confirmed by', 'a negative serum human chorionic gonadotrophin (hCG) test at screen and a negative', 'urine hCG test at Randomization (a local serum hCG test at Randomization is', 'allowed if it can be done, and results obtained, within 24 hours prior to', 'randomization), not breastfeeding, and at least one of the following conditions', 'applies:', 'Not a woman of childbearing potential (WOCBP) as defined in', 'Section 11.4.1', 'OR', 'A WOCBP who agrees to follow the contraceptive guidance in Section 11.4.2', 'during the treatment period from 28 days prior to the first dose of study', '39']\n\n###\n\n", "completion": "END"}